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Abstract: Objective: Our purpose was to
determine whether unexplained elevations in
maternal serum human chorionic gonadotropin (hCG)in the second trimester is associated
with an increased risk of preeclampsia.

from the study. Statistical analyses were perfomed using Student’s t test. Whenever statistical significance was detected, odds ratios
and 95% confidence intervals were also calculated.

Methods: Between April 1992 to April
1995, 610 pregnant women undergoing second trimester triple marker screening for
Down’s syndrome who were delivered at our
institution were included to the study. 81
women with an hCG level greater than 2.0
multiples of median (MOM) served as the
study group and 481 women with hCG levels
<2.0 MOM served as controls. Pregnancies
with fetal chromosomal and structural anomalies and maternal serum alpha-fetprotein
level greater than 2.0 MOM were excluded

Results: Women with elevated hCG levels
were at increased risk for preeclampsia (Odds
ratio 5.93, 95% confidence interval 1.97 to
15.88).
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2
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Introduction
In current screening test for Down’s syndrome
(namely maternal serum alpha-fetoprotein-AFP- human
chronic gonadotropin- hCG-, unconjugated estriol plus
maternal age) an elevated level of hCG is an important
predictor of fetal aneuploidy (1). The positive predictive value of the multiple marker screening test is
approximately 4.3% (2). Besides Down’s syndrome,
triploidy, trophoblastic diseases, and multiple gestations have been associated with elevated hCG levels
(3). In the majority of cases the cause of the elevated
maternal hCG levels is not known. hCG is produced by
placental trophoblasts and excreted directly into the
maternal circulation, and its is possible that abnormal
levels are an early sign of placental dysfunction.
The association between elevated maternal serum
hCG in the second trimester with adverse pregnancy
outcome such as preterm labour, pregnancy-induced
hypertension, and low birth weight has been documented in a few clinical report (4,5).

Conclusion: Pregnancies with unexplained
elevated hCG levels should be regarded as
having a higher risk of preeclampsia.

Key Words: Human chorionic gonadotropin,
second trimester, Preeclampsia.

Pregnancy-induced hypertension is a systemic disease characterised by endothelial injury (6). The disease begins early in pregnancy but overt disease usually appears after the second trimester. Twin and
molar pregnancies which are associated with elevated
hCG levels also carry an increased risk of preeclampsia. As early as 1950, hCG was reported to be elevated in toxemia of pregnancy (7). Some new clinical
reports hypothesized a relation between elevated second trimester hCG levels and hypertensive pregnancy
disorders (8,9).
In view of these findings we undertook this study
to determine whether women with unexplained elevated serum hCG levels are at increased risk for pregnancy-induced hypertension and for preeclampsia in
our population.
Materials and Methods
From April 1992 to April 1995, 610 maternal

*This study was presented in the 5th National Congress on Perinatology, April 16-19, 1996, Ankara
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serum samples were collected for multiple marker
screening test (maternal serum AFP, hCG, unconjugated estriol). In the Hacettepe University Obstetrics
and Gynecology Department tests were performed for
only nondiabetic and singleton pregnancies, and samples collected between 15th and 20th gestational weeks.
Gestational age was estimated by ultrasonographic dating of the pregnancy. Women whose maternal serum
Down’s syndrome screen risk was greater than 1/250
were assigned to the increased-risk group and genetic
counselling and amniocentesis were performed.
Pregnancies with fetal chromosomal and structural
abnormalities or maternal serum AFP levels greater
than 2.0 multiples of median (MOM) were excluded
from the study population. 481 patients who met all
the inclusion or exclusion criteria but with second trimester hCG levels < 2.0 MOM were considered for
inclusion to the control group.
AFP, hCG, and unconjugated estriol were assayed
by the Düzen Laboratories Group, Kavaklıdere, Ankara
using commercially available kits (Kodak). Results were
converted into multiples of the median for each of the
three analytes by using APF Prenatal Interpretive Software from Robert Maciel Associated Inc (Robert
Maciel Associates, Inc. 870 Massachusetts Avenue Post
office box 212).
We obtained the patients’ obstetrics history, biochemical results, and pregnancy outcomes from hospital delivery records.
Pregnancy-induced hypertension was defined as 15
point diastolic or 30 point systolic rise over first trimester blood pressure values; if the first trimester
blood pressure was unknown, it was defined as persistent blood pressure levels > 140/90. The same blood
pressure criteria were used for preeclampsia and
including the criteria of proteinuria of at least 0,5 gr/
L for urine samples collected over 24 hours. Intrauterine growth retardation was defined as birth weight
lower than the 10th percentile for gestational age.

anomalies (n=5) were excluded from the study.
Patients with unexplained elevated AFP levels (n=33)
and both elevated AFP and hCG levels (n=5) were also
excluded from the study, because, it is known that
unexplained AFP elevation in the second trimester of
pregnancy could be associated with adverse pregnancy
outcomes such as low birth weight, fetal death, and
preterm delivery (10,11).
Some characteristics of the study population are in
Table 1. There were no statistically significant differences between study and control subjects with respect
to maternal age (mean±standard deviation) and mean
gravida and mean parity.
Elevated maternal serum hCG levels in the second
trimester of pregnancy were associated with a shortenning of the mean gastation by 1.6 weeks. Elevatad hCG levels were also associated with birth weight
Table 1.

Characteristics of study population.

Characteristic

hCG>2.0 MOM
(n=81)

Control
(n=481)

p

30.2±6.0
2.2±1.3
0.6±0.8
37.0±4.4
2881±952

30.1±5.1
2.3±1.3
0.8±0.8
38.6±1.6
3292±498

NS
NS
NS
<0.01
<0.01

Maternal age (years)
Gravida
Parity
Delivery week
Birth weight (grams)
NS= not significant

reduction of 411 grams compared to controls.
Table 2 shows that the pregnancies of women
with elevated maternal serum hCG levels in the second
trimester were more frequently complicated by pregnancy-induced hypertension (PIH), preeclampsia, intrauterine growth retardation, and abruptio placenta.
The risk of preeclampsia in women with elevated
maternal serum hCG levels in the second trimester
was five times greater than that of the control group
(odds ratio 5.93, 95% confidence interval 1.97 to
15.88).
As a consequence of preeclampsia, the incidence of

Statistical analyses were performed using Student’s
t test. Whenever statistical significance was detected,
odds ratios and 95% confidence intervals were also
calculated.

Table 2.
Outcome

hCG>2.0 MOM
n=81

Control
n=481

Odds Ratio and 95%
confidence interval

Results

PIH
Preeclampsia
Growth retardation
Abrubtio placenta

3 (4.0%)
7 (8.6%)
9 (11%)
2 (2.5%)

12 (2.0%)
8 (1.7%)
11 (2.2%)
3 (0.6%)

1.50 (0.42 to 5.45)
5.93 (1.97 to 15.88)
5.34 (2.14 to 13.34)
4.03(0.66 to 24.53)

Unexplained hCG elevation was observed in 81
patients (13%). Elevations of hCG caused by fetal
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intrauterine growth retardation was 11% among
patients with elevated hCG levels and 2.2% in patients
with normal hCG levels (odds ratio 5.34, 95% confidence interval 2.14 to 13.34).
Although the frequency of PIH among women with
elevated hCG levels was aproximately 1.5 times that
of the controls (oods ratio 1.50, 95% confidence
interval 0.42 to 5.45) and odds ratio of abruptio placenta 4.03, 95% confidence interval 0.66 to 24.53
these findings were not statistically significant because
lower limits of confidence intervals included one.
Discussion
New studies suggest a link between increased hCG
and adverse pregnancy outcomes. Gonen et al
reported that in 284 women with unexplained second
trimester hCG level elevations, they found that these
unexplained elevations increased the relative risk of
hypertension, preterm delivery and fetal growth retardation (4). A few clinical reports document a relation
between elevated second trimester hCG levels and
hypertensive pregnancy disorders (8,9). They suggest
that elevated serum hCG level reflects early placental
disfunction.
PIH rarely appears until the third trimester but the
disease process begins early in pregnancy. The placenta is typically the tissue affected in pregnancies

complicated by hypertension (13). It may be considered that early placental vascular damage in the preeclamptic pregnancies leading to decreased oxygen suppply may result in increased hCG production by hyperplastic cytotrophoblastic cells (8). Indeed, hCG production has been shown to increase when normal
placental villi in organ cultures were maintained under
hypoxic condition (12). It may be hypothesized that
placental health can be predicted by second trimester
maternal serum hCG levels.
Our findings show that women with unexplained
second trimester hCG levels have an increased risk of
preeclampsia, and fetal growth retardation. A higher
incidence of intrauterine growth retardation and preterm delivery with the presence of preeclampsia may
be expected.
We conclude that unexplained elevations of hCG in
the second trimester has a predictive value for subsequent preeclampsia. These pregnancies may require
careful obstetric management to achieve a more favorable outcome.
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